The differential overexpression of CDK1 gene in TCGA tumors lays the foundation for its potential as a tumor therapeutic target, and this differential overexpression involves more tumor types than other tumor targets, which validates its importance at the pan-cancer level. This evidence concerns the gene CDK1 and neoplasm.